文献速递造血干细胞移植与细胞治疗淋巴瘤

首创JAK/ROCK抑制剂罗伐替尼治疗糖皮质激素难治性或依赖性慢性GVHD

A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or -dependent chronic GVHD.
PubMed 文献 · Blood · 2025-01-01

这项1b/2a期多中心开放标签研究纳入44例中重度糖皮质激素难治性或依赖性慢性GVHD患者,评估口服双JAK1/2和ROCK1/2抑制剂罗伐替尼的安全性与疗效。推荐2期剂量为10 mg每日两次,最佳总缓解率为86.4%(95%CI 72.6-94.8),糖皮质激素难治组为72.7%、依赖组为90.9%,12个月无失败生存率85.2%(95%CI 64.5-94.3)。

要点

  • 推荐2期剂量为罗伐替尼10 mg每日两次,两剂量均未出现剂量限制性毒性。
  • 最佳总缓解率86.4%,糖皮质激素难治组72.7%,依赖组90.9%。
  • 88.6%患者减少糖皮质激素剂量,59.1%患者cGVHD症状改善。

核心结论

  • 罗伐替尼耐受性良好且临床缓解率可观,可改善糖皮质激素难治性或依赖性慢性GVHD患者生活质量并减少糖皮质激素剂量需求。

研究设计与样本

  • 1b/2a期、多中心、开放标签研究,采用3+3设计,设罗伐替尼10 mg和15 mg每日两次两个递增剂量及剂量扩展队列。
  • 共纳入44例中重度糖皮质激素难治性或依赖性慢性GVHD患者,10 mg组29例,15 mg组15例。
  • 主要终点为安全性和推荐2期剂量,最佳总缓解率为关键次要终点。
  • 试验注册号NCT04944043。

主要发现

  • 两个剂量均未出现剂量限制性毒性,无罗伐替尼相关不良事件导致停药。
  • 最常见血液学不良事件为贫血(38.6%),≥3级贫血为4.6%。
  • 最佳总缓解率为86.4%(95%CI 72.6-94.8),两个剂量队列间无差异。
  • 最佳总缓解率在糖皮质激素难治组为72.7%,在依赖组为90.9%。
  • 12个月无失败生存率为85.2%(95%CI 64.5-94.3),88.6%患者减少糖皮质激素剂量,59.1%患者cGVHD症状改善。

关键数值与推荐

  • 推荐2期剂量为罗伐替尼10 mg每日两次。
  • 所有受累器官均出现缓解,与既往治疗无关。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rovadicitinib (TQ05105) is a novel, oral dual Janus kinase 1/2 and rho-associated coiled-coil-containing protein kinase-1/2 inhibitor targeting inflammatory and fibrotic components of chronic graft-versus-host disease (cGVHD). This phase 1b/2a, multicenter, open-label study enrolled patients with moderate or severe glucocorticoid-refractory or -dependent cGVHD to evaluate the safety and efficacy of rovadicitinib. The study followed a 3+3 design with 2 escalating doses (rovadicitinib 10 and 15 mg twice daily) and a dose expansion cohort. Primary end points included safety and recommended phase 2 dose (RP2D); the best overall response (BOR) was the key secondary end point. A total of 44 patients were enrolled (29 at 10 mg, 15 at 15 mg twice daily). Rovadicitinib was well tolerated without dose-limiting toxicity at both dosages, and no rovadicitinib-related adverse events (AEs) led to discontinuation. The most prevalent hematological AE was anemia (38.6%), with grade ≥3 of 4.6%. The RP2D was 10 mg twice daily. The BOR was 86.4% (95% confidence interval [CI], 72.6-94.8), with no difference between the 2 dosage cohorts. Besides, BOR was 72.7% in the steroid-refractory cohort and 90.9% in the steroid-dependent cohort. All affected organs exhibited responses regardless of prior therapy. The failure-free survival rate was 85.2% (95% CI, 64.5-94.3) at 12 months. Rovadicitinib reduced corticosteroid doses in 88.6% of patients and improved cGVHD symptoms in 59.1%. Rovadicitinib has favorable tolerability and notable clinical response rates, ameliorating the quality of life and reducing corticosteroid dose requirements in patients with glucocorticoid-refractory or -dependent cGVHD. This trial was registered at www.ClinicalTrials.gov as #NCT04944043.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Zhao YM, Luo Y, Shi JM, et al. A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or -dependent chronic GVHD. Blood. 2025. PMID: 40009501. doi:10.1182/blood.2024026581

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。